Point72 Asset Management L.P. Has $7.16 Million Position in Alto Neuroscience, Inc. (NYSE:ANRO)

Point72 Asset Management L.P. increased its stake in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 73.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,692,153 shares of the company's stock after purchasing an additional 714,461 shares during the quarter. Point72 Asset Management L.P. owned approximately 6.27% of Alto Neuroscience worth $7,158,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its holdings in Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after purchasing an additional 3,139 shares during the last quarter. Deutsche Bank AG lifted its holdings in Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after purchasing an additional 3,629 shares during the last quarter. Rhumbline Advisers lifted its holdings in Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after purchasing an additional 5,008 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Alto Neuroscience by 15.0% in the 4th quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company's stock worth $221,000 after purchasing an additional 6,812 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after purchasing an additional 7,783 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wedbush reiterated a "neutral" rating and set a $4.00 price target on shares of Alto Neuroscience in a report on Thursday, May 15th. William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. Finally, HC Wainwright assumed coverage on Alto Neuroscience in a report on Monday, April 7th. They set a "buy" rating and a $10.00 price target for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Stock Performance

ANRO opened at $2.56 on Tuesday. The stock has a market cap of $69.30 million, a PE ratio of -1.09 and a beta of 1.87. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a 1 year low of $1.60 and a 1 year high of $17.55. The stock's 50 day simple moving average is $2.36 and its 200-day simple moving average is $3.42.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. Sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.